Array Rises On Binimetinib Data, 2016 Regulatory Submissions

Array Biopharma gained 20.6% to close at $4.62 per share on Dec. 16 after the company said it will seek regulatory approvals for binimetinib based on results from the Phase III NEMO clinical trials, which showed the MEK inhibitor nearly doubled median progression-free survival (PFS) for NRAS-mutant melanoma patients to 2.8 months versus 1.5 months for dacarbazine (p

Array Biopharma gained 20.6% to close at $4.62 per share on Dec. 16 after the company said it will seek regulatory approvals for binimetinib based on results from the Phase III NEMO clinical trials, which showed the MEK inhibitor nearly doubled median progression-free survival (PFS) for NRAS-mutant melanoma patients to 2.8 months versus 1.5 months for dacarbazine (p<>

Binimetinib was a casualty of the massive asset swap between Novartis AG and GlaxoSmithKline PLC, in which Novartis acquired GSK's...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anticancer

BMS’s Breyanzi Stands To Further Expand Broad Lymphoma Coverage

 

The drugmaker presented data at a lymphoma meeting showing strong efficacy for the CAR-T in marginal zone lymphoma, the second most common indolent lymphoma.

Early Blood Cancer Data Impresses As Incyte Plots Post-Jakafi Strategy

 
• By 

First results for a first-in-class mutCALR-targeted therapy in essential thrombocythemia presented at EHA point to a lucrative future for the early-stage product.

Quick Listen: Scrip’s Five Must-Know Things

 
• By 

In this week's episode: breaking down big pharma’s executive pay; US vaccine panel upheaval; Merck’s RSV approval; MFN and Japan; and the future of Pfizer and Arvinas’s partnership.

UroGen Gets A First-Ever Bladder Cancer Approval Despite US FDA AdComm ‘No’ Vote

 
• By 

UroGen’s Zusduri was approved despite an advisory committee vote recommending against it in May. It is the first approved drug for a type of recurring bladder cancer.

More from Therapy Areas

Who Dares Wins? Roche Moves Parkinson’s Candidate Into Phase III Despite Near Miss

 

Open-label extension data have persuaded Roche to move prasinezumab into Phase III, where it believes a few tweaks to the study design could turn a near miss into success.

Quick Listen: Scrip’s Five Must-Know Things

 
• By 

In this week's episode: breaking down big pharma’s executive pay; US vaccine panel upheaval; Merck’s RSV approval; MFN and Japan; and the future of Pfizer and Arvinas’s partnership.

UroGen Gets A First-Ever Bladder Cancer Approval Despite US FDA AdComm ‘No’ Vote

 
• By 

UroGen’s Zusduri was approved despite an advisory committee vote recommending against it in May. It is the first approved drug for a type of recurring bladder cancer.